Progress in antiviral therapy in patients with HBV/HCV co-infection

doi:10.3877/cma.j.issn.1674-1358.2017.05.002

Abstract

Abstract:

Hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection is one of the key area in research and clinical practice of viral hepatitis. When compared with single HBV or HCV infection, HBV/HCV co-infection patients show more rapid diseases progression and worse prognosis. Before Direct-acting antivirals (DAAs) were available, Pegylated interferon (PegIFN) + ribavirin nucleos(t)ide analogues (NAs) are first-line therapy for theses patients. Yet, with the development of DAAs, data of DAAs NAs for HBV/HCV co-infection patients were also accumulated. Especially cases about HBV activation after HCV eradiation in HBV/HCV co-infection patients were recently reported, which draw attention of clinics. So the current data about antiviral therapy in HBV/HCV coinfection patients were reviewed.

Key words: Hepatitis B virus, Hepatitis C, Chronic, antiviral agents, prognosis

Yuting Chen, Song Yang, Jun Cheng. Progress in antiviral therapy in patients with HBV/HCV co-infection[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(05): 433-436.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2017.05.002

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2017/V11/I05/433

References 31

[1]	Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection[J]. World J Gastroenterol,2014,20(40):14559- 14567.
[2]	Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment[J]. J Gastroenterol Hepatol,2008,23(4):512-520.
[3]	Liu CJ, Chen PJ. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection[J]. World J Gastroenterol, 2014,20(11):2955-2961.
[4]	Hamzaoui L, El Bouchtili S, Siai K, et al. Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge[J]. Clin Res Hepatol Gastroenterol,2013,37(1):e16-e20.
[5]	Potthoff A, Manns MP, Wedemeyer H. Treatment of HBV/HCV coinfection[J]. Expert Opin Pharmacother,2010,11(6):919-928.
[6]	Liu C J, Chu Y T, Shau W Y, et al. Treatment of patients with dual hepatitis C and B by peginterferon alpha and ribavirin reduced risk of hepatocellular carcinoma and mortality[J]. Gut,2014,63(3):506-514.
[7]	Yu ML, Lee CM, Chen CL, et al. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up[J]. Hepatology,2013,57(6):2135-2142.
[8]	European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016[J]. J Hepatol,2017,66(1):153-194.
[9]	De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge[J]. J Clin Virol,2016,78(1):27-30.
[10]	Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir[J]. Clin Infect Dis,2015,61(8):1304-1306.
[11]	Ende AR, Kim NH, Yeh MM, et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report[J]. J Med Case Rep,2015,9(1):164.
[12]	Mekky MA, Nasr AM, Saleh MA, et al. Virologic and histologic characterisation of dual hepatitis B and C co-infection in Egyptian patients[J]. Arab J Gastroenterol,2013,14(4):143-147.
[13]	Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management[J]. Ann Gastroenterol,2015,28(2):221-228.
[14]	Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection[J]. World J Gastroenterol,2014,20(40):14559- 14567.
[15]	Huang YT, Jen CL, Yang HI, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C[J]. J Clin Oncol,2011,29(27):3643-3650.
[16]	Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients[J]. Hepatology,2006,43(1):100-107.
[17]	Potthoff A, Berg T, Wedemeyer H. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin[J]. Scand J Gastroenterol,2009,44(12):1487-1490.
[18]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol,2017,67(2):370-398.
[19]	Liu CJ, Chen PJ, Chen DS, et al. Perspectives on dual hepatitis B and C infection in Taiwan[J]. J Formos Med Assoc,2016,115(5):298-305.
[20]	Yeh ML, Hung CH, Huang JF, et al. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses[J]. PLoS One,2011,6(6):e20752.
[21]	Liu JY, Sheng YJ, Hu HD, et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis[J]. Virol J,2012,9:186.
[22]	Coppola N, Stanzione M, Messina V, et al. DAA-based regimens in HBsAg/anti-HCV positive patients: the need to control HBV replication to avoid HBV reactivation[J]. J Hepatol,2017,66(Suppl 1):727.
[23]	Preda C, Popescu C, Constantinescu I, et al. Outcome of patients with compensated liver cirrhosis with hepatitis B virus + hepatitis C virus coinfection treated with paritaprevir/ombitasvir/ritonavir, dasabuvir with ribavirin: a national cohort study[J]. J Hepatol,2017,66(Suppl 1):295-296.
[24]	Wang C, Li B, Chen J, et al. Hepatitis B reactivation after interferon-based therapy versus pan-oral direct acting antiviral agents in chronic hepatitis C patients co-infected with hepatitis B virus: a systematic review and meta-analysis[J]. Hepatology,2016,64(Suppl 1):461A.
[25]	Wahle R C, Perez R M, Pereira P F, et al. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection[J]. Braz J Infect Dis,2015,19(5):533-537.
[26]	Coppola N, Pisapia R, Tonziello G, et al. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection[J]. Antivir Ther,2008,13(2):307-318.
[27]	Pontisso P, Gerotto M, Benvegnu L, et al. Coinfection by hepatitis B virus and hepatitis C virus[M]. 1998:137-142.
[28]	Londoño MC, Lens S, Mariño Z, et al. Hepatitis B (HBV) reactivation during anti-hepatitis C (HCV) therapy with interferon (IFN)-free regimens: a prospective study[J]. Hepatology,2016,64(Suppl 1):297A.
[29]	Kawagishi N, Suda G, Onozawa M, et al. Prevalence and risk factors of hepatitis B virus reactivation in interferon-free direct-acting antiviral therapies for hepatitis C[J]. J Hepatol,2017,66(Suppl 1):725-726.
[30]	Belperio PS, Shahoumian TA, Mole LA, et al. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals[J]. Hepatology,2017,66(1):27-36.
[31]	Chen GF, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and metaanalysis[J]. J Hepatol,2017,66(Suppl 1):296-297.

Please choose a citation manager

Content to export